Results 71 to 80 of about 7,348 (160)

Intrathecal baclofen in metachromatic leukodystrophy

open access: yes, 2019
Metachromatic leukodystrophy (MLD) is a rare progressive neurological disorder, often accompanied by motor impairments that are challenging to treat.
Van Rappard, Diane F   +7 more
core   +1 more source

Central Precocious Puberty in a Child With Metachromatic Leukodystrophy

open access: yesFrontiers in Endocrinology, 2018
Metachromatic leucodystrophy (MLD) is a rare inherited lysosomal disorder caused by reduced activity of the enzyme arylsulfatase A with accumulation of sulfatides in the nervous system.
Gilda Belli   +6 more
doaj   +1 more source

Development of the Impact of Juvenile Metachromatic Leukodystrophy on Physical Activities scale

open access: yesJournal of Patient-Reported Outcomes, 2018
Background Metachromatic leukodystrophy (MLD) is a rare disease with three forms based on the age at onset of signs and symptoms. The objective of this study was to develop a caregiver-reported clinical outcome assessment that measures impairments in ...
T. Michelle Brown   +3 more
doaj   +1 more source

Hematopoietic stem cell transplantation for late-onset Metachromatic Leukodystrophy

open access: yes, 2010
Haematopoietic stem cell transplantation has an unproven role in the management of late-onset metachromatic leukodystrophy: theoretically justified through the engraftment of enzyme-replete haematopoietic progenitors and restoration of capacity for ...
Marcus, Robert   +9 more
core   +1 more source

Screening of phytoconstituents from Bacopa monnieri (L.) Pennell and Mucuna pruriens (L.) DC. to identify potential inhibitors against Cerebroside sulfotransferase.

open access: yesPLoS ONE
Cerebroside sulfotransferase (CST) is considered a target protein in developing substrate reduction therapy for metachromatic leukodystrophy. This study employed a multistep virtual screening approach for getting a specific and potent inhibitor against ...
Nivedita Singh, Anil Kumar Singh
doaj   +1 more source

MOESM4 of Peripheral neuropathy in metachromatic leukodystrophy: current status and future perspective

open access: yes, 2019
Additional file 4: Table S3. Ongoing clinical trials on metachromatic leukodystrophy (MLD). A summary of the ongoing clinical trials on treatment for metachromatic leukodystrophy, that are published on https://clinicaltrials.gov/ .
Shanice Beerepoot (7819016)   +5 more
core   +1 more source

Critical issues for the proper diagnosis of Metachromatic Leukodystrophy

open access: yes, 2014
Metachromatic Leukodystrophy is a lysosomal storage disorder caused by Arylsulfatase A deficiency. Diagnosis is usually performed by measurement of enzymatic activity and/or characterization of the gene mutations.
Alessandra Biffi   +12 more
core   +2 more sources

Metachromatic Leukodystrophy: Too Frequent (Mis)Diagnosis

open access: yes, 2018
Recently, Wu et al1 reported the case of an adult patient with late-onset cobalamin C disease who received an incorrect diagnosis of adult metachromatic leukodystrophy (MLD).
Politi, Letterio S.   +2 more
core   +1 more source

Poster Sessions

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Arylsulfatase activity in human urine: quantitative studies on patients with lysosomal disorders including metachromatic leukodystrophy

open access: yes, 1972
A rapid and simple quantitative assay has been employed to measure the arylsulfatase A activity in urine samples from 173 individuals. This group includes three patients with late infantile metachromatic leukodystrophy (MLD), three patients with the ...
Thomas, G.H, Howell, R.R
core   +1 more source

Home - About - Disclaimer - Privacy